Comparative Inpatient Outcomes Among FDA-Approved Chimeric Antigen Receptor T-Cell Products: An Analysis of the National Inpatient Sample

Breyanzi (lisocabtagene maraleucel) - BMS

Kymriah (tisagenlecleucel-T) - Novartis

Carvykti (ciltacabtagene autoleucel) - J&J

Yescarta (axicabtagene ciloleucel) - Gilead

Abecma (idecabtagene vicleucel) - BMS

https://www.sciencedirect.com/science/article/abs/pii/S2152265026031885

Dawood Hasan Syed MD 1; Haider Bin Khalid MD 1; Saumil Parikh MD 2; Abisha Phudong MBBS 1; Ahmed Torshani MD 1; Sudeep Siddappa Malleshappa MD 3; Ahmed Hanif MD 1; Kathan Mehta MBBS MPH 1

Sep 1, 2026